Revestive (teduglutide)

pCPA File Number: 21174

Negotiation Status:

Concluded with an LOI

Indication(s):

Short Bowel Syndrome (SBS)

Sponsor/Manufacturer:

Shire Pharma Canada ULC

CADTH Project Number:

SR0606-000

pCPA Engagement Letter Issued:

2020-02-21

Negotiation Process Concluded:

2020-10-28